After a series of product recalls in April and a disappointing
Integra LifeSciences Holdings Corporation
) witnessed a favorable event. This medical device and implant
company recently gained the CE Mark approval in Europe for its
Integra Smart Cervical Solution.
Following the CE Mark approval, the device will be available
across Europe, the Middle East and Africa. We believe that the
commercialization of innovative products should boost Integra's
international revenues that currently linger at roughly a fourth
of its total revenue.
Integra's latest offering is a therapeutic device for
degenerative diseases that needs stabilization and fusion of two
or more cervical vertebrae. Management claims that Integra Smart
Cervical Solution is a time-saving and user-friendly device that
integrates cervical cage with a 100% synthetic bone substitute.
Moreover, this pre-filled implant is connected to a disposable
inserter to position it securely in the patient's cervical spine.
Integra Smart Cervical Solution improves standards of care by
ensuring stability and lordotic curving in affected patients.
Integra anticipates to launch over 25 innovative products this
year with a focus on regenerative medical offerings. We are
optimistic about the market launch of a modular shoulder system
with a reverse option, which will allow the company to serve a
$650 million shoulder market.
We are positive that Integra's focus on niche technologies will
lend some support amid the contagion of economic problems in
Europe. Moving forward, revenue growth will be supported by new
Currently, the stock carries a Zacks Rank #3 (Hold). While we
remain on the sidelines for Integra, other stocks such as
Biogen Idec Inc.
Protalix BioTherapeutics Inc.
) are worth considering. Both are Zacks Rank #1 (Strong Buy)
), carrying a Zacks Rank #2 (Buy) also warrants a look.
AFFYMAX INC (AFFY): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
INTEGRA LIFESCI (IART): Free Stock Analysis
PROTALIX BIOTHR (PLX): Free Stock Analysis
To read this article on Zacks.com click here.